相关实验视频
Updated: May 12, 2026

06:35
Cell Membrane Repair Assay Using a Two-photon Laser Microscope
Published on: January 2, 2018
12.4K
调节和治疗:铁病在DLBCLL中的作用
Yifan Wang1,2, Zhengmei He1,2, Xinyu Dong2,3
1Department of Hematology, The Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University, Huai'an, China.
Frontiers in pharmacology
|January 21, 2025
概括
针对细胞死亡途径铁亡的新疗法对扩散型大B细胞淋巴瘤 (DLBCL) 有前途. 对铁亡相关基因和诱导体的研究为DLBCL和其他血液癌症提供了新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 细胞生物学 细胞生物学
- 血液学 血液学 血液学
背景情况:
- 扩散性大B细胞淋巴瘤 (DLBCL) 是最常见的B细胞非霍奇金淋巴瘤 (NHL).
- 很大一部分DLBCL患者经历了疾病复发或原发性折射性,需要新的治疗方法.
- 细胞死亡的调节形式铁亡已经成为影响瘤进展和治疗反应的关键因素.
研究的目的:
- 审查在DLBCL的背景下了解铁亡的最新进展.
- 突出在DLBCL中关键的铁灭相关基因 (FRG) 的作用.
- 探索ferroptosis诱导剂在DLBCL治疗中的临床潜力.
主要方法:
- 文献综述侧重于铁灭机制及其与DLBCL相关性.
- 分析了研究研究与铁亡相关的基因,如STAT3,Nrf2和ZEB1.1.的研究.
- 对DLBCL治疗中的铁灭诱导剂 (例如,IKE,α-KG,DMF,APR-246) 的临床数据的检查.
主要成果:
- 铁亡途径的调节显著影响了包括DLBCL在内的血液性恶性瘤中的瘤细胞生长.
- 特定的与铁化相关的基因 (STAT3,Nrf2,ZEB1) 与DLBCL进展有关.
- 几种铁致死诱导剂正在临床研究中,以确定它们在DLBCL中的治疗功效.
结论:
- 向铁亡为新型DLBCL疗法提供了一个有希望的途径.
- 与铁亡相关的基因和诱导剂为治疗DLBCL和其他血液恶性瘤提供了新的策略.
- 为了改善患者的治疗结果,需要对铁灭机制和临床应用进行进一步的研究.
相关概念视频
Neural Regulation
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
Lysosomal Hydrolases
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Receptor Downregulation in MVBs
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
Necrosis
Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become anucleated and die, but their...
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become anucleated and die, but their...

